Literature DB >> 27668046

Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis.

Loretta Fala.   

Abstract

Entities:  

Year:  2016        PMID： 27668046      PMCID： PMC5013855     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  4 in total

Review 1.  Evaluating the economic burden of psoriasis in the United States.

Authors:  Jacqueline Vanderpuye-Orgle; Yang Zhao; Jackie Lu; Anshu Shrestha; Alison Sexton; Seth Seabury; Mark Lebwohl
Journal:  J Am Acad Dermatol       Date:  2015-04-14       Impact factor: 11.527

2.  Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Authors:  A Blauvelt; J C Prinz; A B Gottlieb; K Kingo; H Sofen; M Ruer-Mulard; V Singh; R Pathan; C Papavassilis; S Cooper
Journal:  Br J Dermatol       Date:  2014-12-11       Impact factor: 9.302

3.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

4.  Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).

Authors:  C Paul; J-P Lacour; L Tedremets; K Kreutzer; S Jazayeri; S Adams; C Guindon; R You; C Papavassilis
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-09-22       Impact factor: 6.166
  4 in total
  10 in total

1.  Microglial GPR56 is the molecular target of maternal immune activation-induced parvalbumin-positive interneuron deficits.

Authors:  Diankun Yu; Tao Li; Jean-Christophe Delpech; Beika Zhu; Priya Kishore; Tatsuhiro Koshi; Rong Luo; Karishma J B Pratt; Galina Popova; Tomasz J Nowakowski; Saul A Villeda; Xianhua Piao
Journal:  Sci Adv       Date:  2022-05-06       Impact factor: 14.957

2.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

Authors:  Désirée van der Heijde; Atul Deodhar; James C Wei; Edit Drescher; Dona Fleishaker; Thijs Hendrikx; David Li; Sujatha Menon; Keith S Kanik
Journal:  Ann Rheum Dis       Date:  2017-01-27       Impact factor: 19.103

3.  Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis.

Authors:  Li Zhang; Hua Yang; Qihong Chen; Jing Zhao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

4.  First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis.

Authors:  Nuria Tubau-Juni; Raquel Hontecillas; Andrew Leber; Panita Maturavongsadit; Jyoti Chauhan; Josep Bassaganya-Riera
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

5.  Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.

Authors:  Katarzyna Galica; Aleksandra Lesiak; Magdalena Ciążyńska; Marcin Noweta; Igor Bednarski; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2020-07-11       Impact factor: 1.837

6.  Comparison of Efficacy of Anti-interleukin-17 in the Treatment of Psoriasis Between Caucasians and Asians: A Systematic Review and Meta-Analysis.

Authors:  Danyi Zhang; Jianing Qiu; Xing Liao; Yi Xiao; Minxue Shen; Yaxiong Deng; Danrong Jing
Journal:  Front Med (Lausanne)       Date:  2022-01-25

7.  The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

Authors:  Ahmed H Seddik; Nima Melzer; Foteini Tsotra; Dennis A Ostwald
Journal:  Pharmacoecon Open       Date:  2021-10-19

8.  Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.

Authors:  Yamin Shu; Yufeng Ding; Yanxin Liu; Pan Wu; Xucheng He; Qilin Zhang
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

9.  Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling.

Authors:  Amany El-Shahawy Abdel-Maged; Amany M Gad; Laila Ahmed Rashed; Samar S Azab; Eman A Mohamed; Azza S Awad
Journal:  Mol Neurobiol       Date:  2020-06-08       Impact factor: 5.682

Review 10.  The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.

Authors:  Ana Copaescu; Olivia Smibert; Andrew Gibson; Elizabeth J Phillips; Jason A Trubiano
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.